Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesMannKind Corp

MannKind Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
4.19 USD -0.04 ( 0.95%)
Last update at 2026-11-11T21:27:00Z
VOLUME
3228674
Market Cap
1144.70M

Momentum Score

…

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.15
Low
4.24
High
52 Week Price Range
2.23
Low
6.51
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

MannKind Corporation develops and commercializes inhaled therapeutic products using its Technosphere platform, with Afrezza as its inhalable insulin offering for diabetes. Long-term growth may be driven by wider adoption of Afrezza, potential expansion of indications or licensing of the inhalation platform, and better commercial execution and reimbursement outcomes that could support revenue and partnership development.
Key risks include limited current commercial traction and cash flow, intense competition from injectable insulins and GLP‑1 therapies, potential need for additional financing, and regulatory and reimbursement hurdles.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.23
Dividend Yield
-
Revenue TTM
393.63M
Revenue Per Share
1.42
Gross Profit TTM
296.74M
Debt / Equity
-9.28
ROE
-
Net Debt
398.50M
ROCE
2.45%
Diluted EPS TTM
-0.14

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1.41M 30.52M -10.38M -87.40M -80.93M
Net income 5.86M 27.59M -11.94M -112.17M -91.79M
Selling general administrative 144.13M 94.33M 42.54M 37.72M 77.42M
Selling and marketing expenses - - 51.78M 53.75M -
Gross profit 287.81M 208.90M 136.19M 42.27M 36.59M
Reconciled depreciation 12.28M 9.04M 8.44M 9.11M 5.47M
Ebit 15.24M 68.50M 10.59M -68.92M -53.48M
Ebitda 27.52M 77.47M 15.13M -66.51M -53.61M
Depreciation and amortization 12.28M 8.97M 4.54M 2.41M -0.13M
Non operating income net other - - - -8.28M -18.70M
Operating income 38.80M 72.59M 8.68M -68.92M -53.48M
Other operating expenses 310.17M 212.92M 190.28M 168.69M 128.93M
Interest expense 13.83M 37.98M 25.16M 24.77M 16.58M
Tax provision -4.46M 2.93M 1.56M 0.00M 0.00M
Interest income 8.05M 12.62M 5.39M 2.51M 0.11M
Net interest income -29.98M -25.37M -19.71M -22.26M -16.46M
Non recurring - - - - 0.11M
Income tax expense -4.46M 2.93M 1.56M 24.77M 10.87M
Total revenue 348.97M 285.50M 198.96M 99.77M 75.44M
Total operating expenses 249.00M 136.31M 127.51M 111.19M 90.07M
Cost of revenue 61.16M 76.60M 62.77M 57.50M 38.86M
Total other income expense net -37.39M -42.07M -19.05M -18.48M -27.44M
Net income from continuing ops 5.86M 27.59M -31.29M -87.40M -80.93M
Net income applicable to common shares - - - -87.40M -80.93M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 792.18M 393.84M 475.20M 295.28M 321.16M
Intangible assets 5.07M 5.26M 1.07M 1.15M -
Other current assets 46.55M 31.36M 34.35M 25.48M 3.48M
Total liab 843.20M 472.66M 721.37M 545.82M 530.51M
Total stockholder equity -51.02M -78.82M -246.17M -250.54M -209.35M
Other current liab 97.43M 62.59M 53.48M 44.95M 33.59M
Common stock 3.08M 3.03M 2.70M 2.64M 2.52M
Capital stock 3.08M 3.03M 2.70M 2.64M 2.52M
Retained earnings -3195.96M -3201.82M -3229.41M -3217.47M -3130.07M
Other liab - - - 105.18M 106.39M
Good will 67.59M 1.93M 1.93M 2.43M -
Other assets - - - 9.72M 5.19M
Cash 74.88M 46.34M 238.48M 69.77M 124.18M
Total current liabilities 171.03M 81.84M 104.12M 67.30M 48.35M
Current deferred revenue 15.33M 12.41M 9.09M 1.73M 0.83M
Net debt 398.50M 1.36M 143.90M 313.14M 258.56M
Short term debt 49.24M 13.12M 31.98M 9.56M 6.98M
Short long term debt 36.28M - 20.00M 9.56M 6.98M
Short long term debt total 473.38M 47.70M 382.38M 382.91M 382.74M
Other stockholder equity 3141.74M 3118.86M 2980.54M 2964.29M 2918.20M
Property plant equipment - - - 45.13M 36.61M
Total current assets 291.58M 268.31M 373.39M 234.90M 219.74M
Long term investments 5.01M 5.48M 7.16M 1.96M 56.62M
Net tangible assets - - - -254.12M -209.35M
Short term investments 96.46M 150.92M 56.62M 101.08M 79.93M
Net receivables 38.37M 11.80M 15.40M 16.80M 4.99M
Long term debt 318.36M 36.05M 248.70M 368.00M 223.94M
Inventory 35.31M 27.89M 28.55M 21.77M 7.15M
Accounts payable 9.03M 6.79M 9.58M 11.05M 6.96M
Accumulated other comprehensive income 0.12M 1.11M - - -
Common stock total equity - - - 2.64M 2.52M
Retained earnings total equity - - - -3217.47M -3130.07M
Non currrent assets other 340.50M 27.49M 2.74M 9.72M 8.19M
Non current assets total 500.60M 125.54M 101.81M 60.39M 101.42M
Capital lease obligations 12.80M 11.64M 3.92M 5.34M 1.04M
Long term debt total - - - 225.40M 223.94M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 57.51M -96.65M 20.92M 4.87M -137.07M
Change to liabilities - - - -1.58M 15.14M
Total cashflows from investing activities -304.80M -96.65M - 4.87M -151.54M
Net borrowings 325.00M -133.17M - -0.02M 177.68M
Total cash from financing activities 315.10M -137.27M 136.80M 21.41M 270.27M
Change to operating activities - - - -24.77M -4.63M
Net income 5.86M 27.59M -11.94M -87.40M -80.93M
Change in cash 28.55M -191.40M 168.71M -54.42M 57.02M
Begin period cash flow 47.08M 238.48M 69.77M 124.18M 67.16M
End period cash flow 75.63M 47.08M 238.48M 69.77M 124.18M
Total cash from operating activities 18.25M 42.51M 33.91M -80.68M -61.71M
Issuance of capital stock 0.00M 0.00M 7.28M 19.79M 1.99M
Depreciation 12.28M 9.04M 5.80M 9.11M 5.47M
Other cashflows from investing activities -16.41M 128.71M - -20.34M -3.00M
Dividends paid - - - - 0.50M
Change to inventory 10.40M -3.20M -11.35M -5.67M -4.08M
Change to account receivables -4.76M 2.65M 2.35M -11.81M -0.78M
Sale purchase of stock -3.26M - -10.16M 19.41M -0.50M
Other cashflows from financing activities -5.91M 1.99M -8.34M -0.06M 99.71M
Change to netincome - - - 10.86M 24.84M
Capital expenditures 4.57M 9.69M 42.44M 7.59M 11.47M
Change receivables - - - -11.81M -0.78M
Cash flows other operating - - - 8.80M -20.12M
Cash and cash equivalents changes - - - -54.42M 57.02M
Change in working capital -86.35M -36.47M 14.63M -24.05M -17.73M
Stock based compensation 24.20M 21.36M 17.65M 13.45M 12.20M
Other non cash items 67.23M 21.00M 13.21M 8.22M 6.63M
Free cash flow 13.69M 32.82M -8.54M -88.27M -73.17M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MNKD
MannKind Corp		 -0.04
0.95%		 4.19 - 28.90 2.91 187.85 3.63 70.14
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

1 Casper Street, Danbury, CT, United States, 06810

818 661 5000

https://mannkindcorp.com

591

Name Title Year Born
Dr. Michael E. Castagna Pharm.D. CEO & Director 1977
Mr. Steven B. Binder Chief Financial Officer 1963
Mr. Joseph Kocinsky M.B.A., M.S. Chief Technology Officer 1964
Dr. David B. Thomson Exec. VP, Gen. Counsel & Sec. 1967
Dr. Stuart A. Tross Ph.D. Chief People & Workplace Officer 1967
Mr. Thomas Hofmann M.D., Ph.D. Chief Scientific Officer NA
Ms. Rosabel Realica Alinaya VP of Investor Relations & Treasury 1961
Mr. John F. Bedard Sr. VP of Worldwide Regulatory Affairs 1950
Mr. James Patrick McCauley Jr., J.D., M.B.A. Chief Commercial Officer 1966
Ms. Lauren M. Sabella Executive VP & COO 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…